0000899243-18-018711.txt : 20180629
0000899243-18-018711.hdr.sgml : 20180629
20180629160108
ACCESSION NUMBER: 0000899243-18-018711
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180627
FILED AS OF DATE: 20180629
DATE AS OF CHANGE: 20180629
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ross Leonard S
CENTRAL INDEX KEY: 0001458753
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51122
FILM NUMBER: 18929273
MAIL ADDRESS:
STREET 1: C/O PSIVIDA CORP
STREET 2: 400 PLEASANT STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001314102
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 262774444
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-926-5000
MAIL ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida Corp.
DATE OF NAME CHANGE: 20080619
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida LTD
DATE OF NAME CHANGE: 20050111
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-27
0
0001314102
EyePoint Pharmaceuticals, Inc.
EYPT
0001458753
Ross Leonard S
C/O EYEPOINT PHARMACEUTICALS, INC.
480 PLEASANT STREET
WATERTOWN
MA
02472
0
1
0
0
See Remarks
Common Stock
2018-06-27
4
M
0
6666
A
16666
D
Common Stock
2018-06-27
4
F
0
1904
1.86
D
14762
D
Restricted Stock Units
2018-06-27
4
M
0
6666
0.00
D
Common Stock
6666
13334
D
Restricted stock units convert into common stock on a one-for-one basis.
On June 27, 2017, the reporting person was granted 20,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the insider's exercise of his withholding right following the vesting of the restricted stock units.
Vice President of Finance and Chief Accounting Officer
/s/ John Mercer, Attorney-in-Fact
2018-06-29